Kurs & Likviditet
-9,12%
|
0,75 MNOK
Kursutveckling och likviditet under dagen för detta pressmeddelande
Kalender
2024-11-06 | Kvartalsrapport 2024-Q3 |
2024-08-22 | Kvartalsrapport 2024-Q2 |
2024-06-06 | Ordinarie utdelning AZT 0.00 NOK |
2024-06-05 | Årsstämma 2024 |
2024-05-08 | Kvartalsrapport 2024-Q1 |
2024-02-01 | Bokslutskommuniké 2023 |
2023-11-02 | Kvartalsrapport 2023-Q3 |
2023-08-17 | Kvartalsrapport 2023-Q2 |
2023-06-07 | Ordinarie utdelning AZT 0.00 NOK |
2023-06-06 | Årsstämma 2023 |
2023-05-04 | Kvartalsrapport 2023-Q1 |
2023-02-02 | Bokslutskommuniké 2022 |
2022-10-27 | Kvartalsrapport 2022-Q3 |
2022-08-18 | Kvartalsrapport 2022-Q2 |
2022-06-23 | Årsstämma 2022 |
2022-05-27 | Ordinarie utdelning AZT 0.00 NOK |
2022-04-28 | Kvartalsrapport 2022-Q1 |
2022-01-27 | Bokslutskommuniké 2021 |
2021-10-28 | Kvartalsrapport 2021-Q3 |
2021-08-19 | Kvartalsrapport 2021-Q2 |
2021-05-21 | Ordinarie utdelning AZT 0.00 NOK |
2021-05-20 | Årsstämma 2021 |
2021-04-22 | Kvartalsrapport 2021-Q1 |
2021-01-28 | Bokslutskommuniké 2020 |
2020-10-22 | Kvartalsrapport 2020-Q3 |
2020-08-19 | Kvartalsrapport 2020-Q2 |
2020-05-15 | Ordinarie utdelning AZT 0.00 NOK |
2020-05-14 | Årsstämma 2020 |
2020-04-23 | Kvartalsrapport 2020-Q1 |
2020-01-30 | Bokslutskommuniké 2019 |
2020-01-06 | Extra Bolagsstämma 2020 |
2019-10-24 | Kvartalsrapport 2019-Q3 |
2019-08-15 | Kvartalsrapport 2019-Q2 |
2019-05-16 | Ordinarie utdelning AZT 0.00 NOK |
2019-05-15 | Årsstämma 2019 |
2019-04-30 | Kvartalsrapport 2019-Q1 |
2019-01-30 | Bokslutskommuniké 2018 |
2018-10-18 | Kvartalsrapport 2018-Q3 |
2018-08-16 | Kvartalsrapport 2018-Q2 |
2018-05-09 | Ordinarie utdelning AZT 0.00 NOK |
2018-05-07 | Årsstämma 2018 |
2018-04-26 | Kvartalsrapport 2018-Q1 |
2018-02-01 | Bokslutskommuniké 2017 |
2017-10-19 | Kvartalsrapport 2017-Q3 |
2017-08-17 | Kvartalsrapport 2017-Q2 |
2017-05-12 | Ordinarie utdelning AZT 0.00 NOK |
2017-05-11 | Årsstämma 2017 |
2017-04-27 | Kvartalsrapport 2017-Q1 |
2017-02-02 | Bokslutskommuniké 2016 |
2016-10-26 | Kvartalsrapport 2016-Q3 |
2016-08-17 | Kvartalsrapport 2016-Q2 |
2016-05-12 | Ordinarie utdelning AZT 0.00 NOK |
2016-05-11 | Årsstämma 2016 |
2016-04-19 | Kvartalsrapport 2016-Q1 |
2016-02-11 | Bokslutskommuniké 2015 |
2016-02-11 | Kapitalmarknadsdag 2016 |
2015-11-03 | Kvartalsrapport 2015-Q3 |
2015-08-13 | Kvartalsrapport 2015-Q2 |
2015-05-13 | Ordinarie utdelning AZT 0.00 NOK |
2015-05-12 | Årsstämma 2015 |
2015-05-05 | Kvartalsrapport 2015-Q1 |
2015-02-17 | Bokslutskommuniké 2014 |
2014-11-05 | Kvartalsrapport 2014-Q3 |
2014-08-13 | Kvartalsrapport 2014-Q2 |
2014-05-15 | Ordinarie utdelning AZT 0.00 NOK |
2014-05-14 | Årsstämma 2014 |
2014-04-30 | Kvartalsrapport 2014-Q1 |
2014-02-14 | Bokslutskommuniké 2013 |
2013-11-01 | Kvartalsrapport 2013-Q3 |
2013-08-09 | Kvartalsrapport 2013-Q2 |
2013-06-13 | Kapitalmarknadsdag 2013 |
2013-05-28 | Ordinarie utdelning |
2013-05-27 | Årsstämma 2013 |
2013-05-07 | Kvartalsrapport 2013-Q1 |
2013-02-01 | Extra Bolagsstämma 2013 |
2013-01-07 | Bokslutskommuniké 2012 |
2012-11-06 | Kvartalsrapport 2012-Q3 |
2012-08-10 | Kvartalsrapport 2012-Q2 |
2012-05-07 | Ordinarie utdelning AZT 0.00 NOK |
2012-05-07 | Årsstämma 2012 |
2012-05-07 | Kvartalsrapport 2012-Q1 |
2012-02-21 | Bokslutskommuniké 2011 |
2011-11-08 | Kvartalsrapport 2011-Q3 |
2011-08-10 | Kvartalsrapport 2011-Q2 |
2011-05-13 | Kvartalsrapport 2011-Q1 |
2011-05-13 | Årsstämma 2011 |
2011-05-12 | Ordinarie utdelning |
2011-02-17 | Bokslutskommuniké 2010 |
2010-11-12 | Kvartalsrapport 2010-Q3 |
2010-08-10 | Kvartalsrapport 2010-Q2 |
2010-05-11 | Kvartalsrapport 2010-Q1 |
2010-05-04 | Årsstämma 2010 |
2010-03-03 | Bokslutskommuniké 2009 |
Beskrivning
Land | Norge |
---|---|
Lista | OB Match |
Sektor | Hälsovård |
Industri | Bioteknik |
2019-10-24 07:00:11
Tromsø, Norway, 24 October 2019 - Biotec Pharmacon (OSE: Biotec) announces its third quarter and first nine months 2019 results. Highlights for Q3 2019 and the first nine months: . Group sales marginally up from last year to NOK 22.5 million (Q3 2018: NOK 22.1 million). . Gross profit for the Group improved 8% to NOK 15.7 million (Q3 2018: NOK 14.6 million) due to increased sales in the enzyme business. . ArcticZymes had third quarter sales of NOK 12.0 million growing by 23% (Q3 2018: NOK 9.8 million). . Woulgan® had lower than expected sales. Sales were NOK 1.1 million but shows growth compared to same quarter last year. Strategy to be reviewed by management and the Board of Directors. . The Group delivered positive EBITDA with NOK 0.8 million (Q3 2018: NOK 0.6 million). . Cash-flow for the quarter was NOK 0.7 million (Q3 2018: NOK -7.0 million). For more information, please contact Børge Sørvoll CFO borge.sorvoll@biotec.no +47 952 90187 About Biotec Pharmacon ASA Biotec Pharmacon is a Norwegian life sciences company focused on specialized, novel enzyme and immunomodulating beta-glucan technology. The Biotec Pharmacon Group is creating value from innovation in life science markets via its subsidiaries, ArcticZymes and Biotec BetaGlucans. Its technologies capitalize on more than three decades of world-class research at the Arctic University of Tromsø to offer niche and high tech products in several biotech segments. ArcticZymes develops, manufactures and commercialises novel recombinant enzymes for use in molecular research, In Vitro Diagnostics (IVD) and therapeutics. Biotec BetaGlucans develops, produces and markets immunomodulating beta-glucans addressing high unmet healthcare needs, such as chronic wound healing and as an adjuvant in vaccines against certain types of cancer relapse. Listed on the Oslo Stock Exchange since 2005 under the [Biotec] ticker, Biotec Pharmacon is headquartered in Tromsø, Norway, in the SIVA Innovation Centre. Biotec Pharmacon's unique IP and capabilities are protected via a large portfolio of patents around both enzyme and beta-glucan products. For more information, please visit the website: www.biotec.no.